Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 3
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Systematic benchmarking of single-cell ATAC-sequencing protocols.
De Rop FV, Hulselmans G, Flerin C, Soler-Vila P, Rafels A, Christiaens V, González-Blas CB, Marchese D, Caratù G, Poovathingal S, Rozenblatt-Rosen O, Slyper M, Luo W, Muus C, Duarte F, Shrestha R, Bagdatli ST, Corces MR, Mamanova L, Knights A, Meyer KB, Mulqueen R, Taherinasab A, Maschmeyer P, Pezoldt J, Lambert CLG, Iglesias M, Najle SR, Dossani ZY, Martelotto LG, Burkett Z, Lebofsky R, Martin-Subero JI, Pillai S, Sebé-Pedrós A, Deplancke B, Teichmann SA, Ludwig LS, Braun TP, Adey AC, Greenleaf WJ, Buenrostro JD, Regev A, Aerts S, Heyn H. De Rop FV, et al. Among authors: taherinasab a. Nat Biotechnol. 2023 Aug 3. doi: 10.1038/s41587-023-01881-x. Online ahead of print. Nat Biotechnol. 2023. PMID: 37537502
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia.
Lunghi M, Patriarca A, Greco M, Taherinasab A, Della Starza I, Cavalli M, Gaidano G, Foà R, Chiaretti S. Lunghi M, et al. Among authors: taherinasab a. Leuk Lymphoma. 2021 Mar;62(3):755-757. doi: 10.1080/10428194.2020.1842401. Epub 2020 Nov 5. Leuk Lymphoma. 2021. PMID: 33150814 No abstract available.
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
Fazio F, Cunsolo G, Mancini F, De Propris MS, Piciocchi A, Arena V, Messina M, Ansuinelli M, Taherinasab AT, Apicella V, Vitale A, Chiaretti S, Guarini A, Del Giudice I, Foà R. Fazio F, et al. Among authors: taherinasab at. Leuk Lymphoma. 2022 Jun;63(6):1512-1514. doi: 10.1080/10428194.2022.2032035. Epub 2022 Feb 8. Leuk Lymphoma. 2022. PMID: 35133227 No abstract available.
Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
Braun TP, Estabrook J, Schonrock Z, Curtiss BM, Darmusey L, Macaraeg J, Enright T, Coblentz C, Callahan R, Yashar W, Taherinasab A, Mohammed H, Coleman DJ, Druker BJ, Demir E, Lusardi TA, Maxson JE. Braun TP, et al. Among authors: taherinasab a. Leukemia. 2023 Feb;37(2):478-487. doi: 10.1038/s41375-022-01792-x. Epub 2022 Dec 16. Leukemia. 2023. PMID: 36526735 Free PMC article.
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
Curtiss BM, VanCampen J, Macaraeg J, Kong GL, Taherinasab A, Tsuchiya M, Yashar WM, Tsang YH, Horton W, Coleman DJ, Estabrook J, Lusardi TA, Mills GB, Druker BJ, Maxson JE, Braun TP. Curtiss BM, et al. Among authors: taherinasab a. Leukemia. 2022 Jul;36(7):1781-1793. doi: 10.1038/s41375-022-01594-1. Epub 2022 May 19. Leukemia. 2022. PMID: 35590033 Free PMC article.
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.
Chiaretti S, Taherinasab A, Della Starza I, Canichella M, Ansuinelli M, De Propris MS, Messina M, Spinelli O, Santoro A, De Novi LA, Cardinali D, Schipani M, Arena V, Bassan R, Guarini A, Foà R. Chiaretti S, et al. Among authors: taherinasab a. Leuk Lymphoma. 2023 Feb;64(2):483-486. doi: 10.1080/10428194.2022.2148217. Epub 2022 Dec 19. Leuk Lymphoma. 2023. PMID: 36533589 No abstract available.
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M, Della Starza I, Lauretti A, Elia L, Siravo V, Messina M, De Novi LA, Taherinasab A, Canichella M, Guarini A, Foà R, Chiaretti S. Ansuinelli M, et al. Among authors: taherinasab a. Hematol Oncol. 2021 Dec;39(5):680-686. doi: 10.1002/hon.2913. Epub 2021 Aug 16. Hematol Oncol. 2021. PMID: 34402088 Free PMC article.
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Albertini Petroni G, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foà R. Chiaretti S, et al. Among authors: taherinasab a. Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973. Haematologica. 2021. PMID: 32467145 Free PMC article.